Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00379288 | Study of Mometasone Furoate/Formoterol Combination and Fluticasone/Salmeterol in Persistent Asthmatics Previously Treated With Inhaled Glucocorticosteroids (P04139) | PHASE3 | COMPLETED | 404 | — | — | Jun 1, 2006 | Nov 1, 2007 | May 20, 2024 | - | — |
AEs that are considered Related, Severe, and Serious, as determined by the investigator and using specific criteria defined in the protocol, are included in the primary results.
| Arm | Type | Description |
|---|---|---|
| MF/F 200/10 mcg BID | EXPERIMENTAL | - |
| MF/F 400/10 mcg BID | EXPERIMENTAL | - |
| F/SC 250/50 mcg BID | ACTIVE_COMPARATOR | - |
| F/SC 500/50 mcg BID | ACTIVE_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| mometasone furoate combination MDI 200/10 mcg BID | DRUG | MF/F 200/10 mcg via a metered dose inhaler (MDI) twice daily for 1 year |
| mometasone furoate combination MDI 400/10 mcg BID | DRUG | MF/F 400/10 mcg via a metered dose inhaler (MDI) twice daily for 1 year |
| Fluticasone/Salmeterol 250/50 mcg BID | DRUG | F/SC 250/50 twice daily for 1 year |
| Fluticasone/Salmeterol 500/50 mcg BID | DRUG | F/SC 500/50 twice daily for 1 year |
Inclusion Criteria: * Subjects of either sex and any race, at least 12 years of age, with a diagnosis of asthma of at least 12 months. * Use of medium or high daily dose of ICS (alone or in combination with long-acting beta-agonist \[LABA\]) for at least 12 weeks prior to Screening and have been on...